Just noticed something interesting - Seamus Mulligan, a board member at Jazz Pharmaceuticals, dropped nearly $10M into the stock back in May. That's a pretty solid vote of confidence, right? The purchase was for over 101k shares at around $103 each, which tells me the insiders are betting on the company's direction.

Jazz Pharma is an Ireland-based biotech focused on sleep disorders and cancer treatments. Their portfolio includes some solid products like Xyrem for narcolepsy and a few oncology drugs. They also picked up Epidiolex back in 2021 for epilepsy treatment, which has been a key addition.

Looking at the financials though, it's a mixed picture. Revenue was down slightly (-0.46% recently), and their EPS is in negative territory at -1.52, which isn't great. But here's the thing - the gross margin is strong at 88.35%, showing they've got solid cost control. The valuation metrics look interesting too: P/E of 13.98 and P/S of 1.66 are both below industry averages, suggesting the stock might be underpriced relative to peers.

The debt situation is something to watch - their debt-to-equity ratio at 1.3 is higher than the industry average, so there's more leverage on the balance sheet than you'd ideally want. Still, when Seamus Mulligan and other insiders are buying, it usually means they see upside ahead. Not saying it's a guaranteed win, but insider buying like this is worth paying attention to when you're researching biotech plays.